Program characteristics | Program outcomes | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
First author, year of publication | Calendar year of data collection | Population | Country and HCV prevalence according to CDC[23] | Setting of screening | Duration of screening program | Other tests | Prescreening selection | Media activities | Screening uptake and anti-HCV prevalence (95% CI) | Risk profile of identified HCV cases/Risk factors associated with HCV | Follow-up of HCV-infected individuals |
Groom et al. 2008 [79] | 2000-2001 | Veterans | USA (1.9%): Minneapolis | Veteran Affairs clinic | 2Â years | None | Yes, only those with a risk factor were screened (risk factors not specified) | NR | Scr. uptake: NR | NR | In total, 520/681 were HCV RNA positive of which 430 referred to a specialist, of which 88.8% (382/430) attended an appointment. Of those, 32.5% (124/382) received treatment which was successful in 37.0% (46/124) (SVR). |
Prevalence: 5.5% (681/12485; 95% CI: 5.1-5.9)* | |||||||||||
Outcomes: RNA rate: 76.4% (520/681) Start treatment: 32.5% (124/382) SVR: 37.1% (46/124) | |||||||||||
Mallette et al. 2008 [80] | 1998-2004 | Veterans | USA (1.9%): Providence | GP patients presenting to VA clinics | 5 years and 8 months | None | Yes, only those with a risk factor were screeneda | NR | Scr. uptake: 66.7% (5646/8471) Prevalence: 7.3% (412/5646; 95% CI: 6.6-8.0); without already known positives: 260/5646 = 4.6% (95% CI = 4.1-5.2%)*** | Listed risk factors: - History of IDU - Blood transfusion before 1992 - Intranasal cocaine use - Multiple sex partners - Tattoos | Of the newly diagnosed, 46.9% (122/260) had chronic HCV, of which 46.7% (57/122) were treatment eligible. Of those, 31.6% (18/57) received treatment and 33.3% (6/18) reached an SVR. Outcomes: RNA rate: 46.9% (122/260) Start treatment: 14.8% (18/122) SVR: 33.3% (6/18) |
Cheung et al. 2006 [81] | 2000-2001 | Veterans | USA (1.9%): Palo Alto | VA clinic | 12Â months | None | Yes, if not previously tested, and if one or more risk factors were reportedb | NR | Scr. uptake: NR | NR | In total, 362/536 patients were evaluated of which 84.8% (307/362) had chronic HCV. Of those, 18.6% (57/307) were treatment eligible of whom 24.6% (14/57) completed treatment with long-term follow-up, and 35.7% (5/14) achieved SVR. |
Prevalence: 5.0% (536/10751; 95% CI: 4.6-5.4)*** | |||||||||||
Outcomes: RNA rate: 84.8% (307/362) Start treatment: NR SVR: 35.7% (5/14) | |||||||||||
Rifai et al. 2006 [82] | 2000-2001 | Veterans | USA (1.9%): Virginia | Rural VA clinic | 22Â months | None | Yes, only non-IDU substance using veterans who were admitted to a substance-use residential and rehabilitation treatment program were tested | NR | Scr. uptake: 99.4% (338/340) Prevalence: 23.1% CHCV (78/338; 95% CI: 18.9-27.9) (incl. 2 who knew already)**** | Univariate regr. analysis: - Cocaine snorting - History of IDU | In total, 48.7% (38/78) of the patients remained abstinent for 6 months and 30 were indicated for treatment and received treatment. In 46.7% (14/30) treatment was successful (SVR). |
Outcomes: RNA rate: n/a Start treatment: 81.1% (30/37) SVR: 46.7% (14/30) | |||||||||||
Zuniga et al. 2006 (abstract) [83] | 2001-2003 | Veterans | USA (1.9%): Suffolk County, Long Island | Primary-care outpatient departments of the Northport VA clinic (suburban VA hospital) | 27 months | None | Yes, only those with a risk factor were screenedc | No | Scr. uptake: 41.9% (2263/5400) Prevalence: 4.6% CHCV (103/2263; 95% CI: 3.8-5.5)**** | Multivariable regr. analysis - Age 40–54 yrs - Black race - History of IDU - Service during Vietnam era - Blood transfusion prior to 1992 - Tattoo or repeated body piercing - History of abnormal LFTs | NR Outcomes: RNA rate: n/a Start treatment: NR SVR: NR |